Jeffrey S. Wasser

3.6k total citations
48 papers, 2.0k citations indexed

About

Jeffrey S. Wasser is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, Jeffrey S. Wasser has authored 48 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Hematology, 16 papers in Oncology and 11 papers in Genetics. Recurrent topics in Jeffrey S. Wasser's work include Platelet Disorders and Treatments (26 papers), Blood groups and transfusion (16 papers) and Cancer Immunotherapy and Biomarkers (14 papers). Jeffrey S. Wasser is often cited by papers focused on Platelet Disorders and Treatments (26 papers), Blood groups and transfusion (16 papers) and Cancer Immunotherapy and Biomarkers (14 papers). Jeffrey S. Wasser collaborates with scholars based in United States, United Kingdom and France. Jeffrey S. Wasser's co-authors include Roger M. Lyons, James B. Bussel, David J. Kuter, Yufan Zhao, Omid Hamid, Todd M. Bauer, David C. Smith, Emmett V. Schmidt, Ani Sarkis Balmanoukian and Janet Maleski and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Jeffrey S. Wasser

48 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jeffrey S. Wasser United States 20 909 587 385 327 251 48 2.0k
G.J. Ossenkoppele Netherlands 34 1.6k 1.7× 1.1k 1.9× 607 1.6× 210 0.6× 812 3.2× 84 3.3k
Pietro Pioltelli Italy 23 969 1.1× 319 0.5× 213 0.6× 126 0.4× 302 1.2× 80 2.0k
Michael Schleuning Germany 24 1.3k 1.4× 353 0.6× 467 1.2× 101 0.3× 57 0.2× 58 1.8k
Ulf‐Henrik Mellqvist Sweden 24 1.4k 1.5× 664 1.1× 486 1.3× 108 0.3× 114 0.5× 60 2.2k
Katsuji Shinagawa Japan 27 815 0.9× 548 0.9× 428 1.1× 105 0.3× 354 1.4× 108 1.9k
Norifumi Tsukamoto Japan 25 826 0.9× 433 0.7× 440 1.1× 138 0.4× 706 2.8× 139 2.1k
Akihiko Yokohama Japan 19 594 0.7× 379 0.6× 794 2.1× 97 0.3× 361 1.4× 135 1.9k
Vamsi Kota United States 19 887 1.0× 408 0.7× 126 0.3× 136 0.4× 98 0.4× 156 1.4k
Belinda R. Avalos United States 23 1.0k 1.1× 779 1.3× 709 1.8× 125 0.4× 91 0.4× 100 2.1k
Federico Campigotto United States 17 645 0.7× 342 0.6× 297 0.8× 95 0.3× 143 0.6× 40 2.0k

Countries citing papers authored by Jeffrey S. Wasser

Since Specialization
Citations

This map shows the geographic impact of Jeffrey S. Wasser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey S. Wasser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey S. Wasser more than expected).

Fields of papers citing papers by Jeffrey S. Wasser

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey S. Wasser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey S. Wasser. The network helps show where Jeffrey S. Wasser may publish in the future.

Co-authorship network of co-authors of Jeffrey S. Wasser

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey S. Wasser. A scholar is included among the top collaborators of Jeffrey S. Wasser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey S. Wasser. Jeffrey S. Wasser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hamid, Omid, Alberto Chiappori, John A. Thompson, et al.. (2022). First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 10(10). e005471–e005471. 37 indexed citations
2.
McGrath, Leah J., Carrie M. Nielson, Bradley Saul, et al.. (2021). Lessons Learned Using Real‐World Data to Emulate Randomized Trials: A Case Study of Treatment Effectiveness for Newly Diagnosed Immune Thrombocytopenia. Clinical Pharmacology & Therapeutics. 110(6). 1570–1578. 4 indexed citations
3.
Cuker, Adam, Jenny M. Despotovic, Rachael F. Grace, et al.. (2020). Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method. Research and Practice in Thrombosis and Haemostasis. 5(1). 69–80. 15 indexed citations
4.
McGrath, Leah J., Robert A. Overman, Anjali Sharma, et al.. (2020). <p>Treatment Patterns Among Adults with Primary Immune Thrombocytopenia Diagnosed in Hematology Clinics in the United States</p>. Clinical Epidemiology. Volume 12. 435–445. 9 indexed citations
5.
Ménoret, Antoine, et al.. (2018). A novel biologic platform elicits profound T cell costimulatory activity and antitumor immunity in mice. Cancer Immunology Immunotherapy. 67(4). 605–613. 4 indexed citations
6.
Villaruz, Liza C., Bryan J. Schneider, Todd M. Bauer, et al.. (2018). OA05.02 Epacadostat Plus Pembrolizumab in Patients with Non-Small Cell Lung Cancer: Phase 1/2 Results from ECHO-202/KEYNOTE-037. Journal of Thoracic Oncology. 13(10). S330–S330. 3 indexed citations
7.
Li, Shuling, et al.. (2017). Rate of bleeding-related episodes in elderly patients with primary immune thrombocytopenia: a retrospective cohort study. Current Medical Research and Opinion. 34(2). 209–216. 7 indexed citations
8.
9.
Wasser, Jeffrey S., et al.. (2016). Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?. Expert Opinion on Biological Therapy. 16(5). 655–674. 20 indexed citations
10.
Mar, Nataliya, James J. Vredenburgh, & Jeffrey S. Wasser. (2015). Targeting HER2 in the treatment of non-small cell lung cancer. Lung Cancer. 87(3). 220–225. 86 indexed citations
11.
Wasser, Jeffrey S., et al.. (2015). Tumor-Unrelated CD4 T Cell Help Augments CD134 plus CD137 Dual Costimulation Tumor Therapy. The Journal of Immunology. 195(12). 5816–5826. 15 indexed citations
12.
Wasser, Jeffrey S., et al.. (2015). Refractory Immune Thrombocytopenic Purpura and Cytomegalovirus Infection: A Call for a Change in the Current Guidelines. Mediterranean Journal of Hematology and Infectious Diseases. 8(1). 2016010–2016010. 14 indexed citations
13.
Cines, Douglas B., Terry Gernsheimer, Jeffrey S. Wasser, et al.. (2015). Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim. International Journal of Hematology. 102(3). 259–270. 67 indexed citations
14.
15.
Kuter, David J., James B. Bussel, Adrian C. Newland, et al.. (2013). Long‐term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. British Journal of Haematology. 161(3). 411–423. 203 indexed citations
16.
Wasser, Jeffrey S., Ralph V. Boccia, Roger M. Lyons, et al.. (2011). Use of Rituximab in a Study Comparing the Thrombopoietin Mimetic Romiplostim with Standard of Care (SOC) in Patients with Immune Thrombocytopenia (ITP),. Blood. 118(21). 3282–3282. 1 indexed citations
17.
Kuter, David J., James B. Bussel, Adrian C. Newland, et al.. (2008). Long-Term Treatment with Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura (ITP): 3-Year Update from An Open-Label Extension Study. Blood. 112(11). 402–402. 13 indexed citations
18.
Kuter, David J., James B. Bussel, James N. George, et al.. (2006). Long-Term Dosing of AMG 531 in Thrombocytopenic Patients with Immune Thrombocytopenic Purpura: 48-Week Update.. Blood. 108(11). 476–476. 28 indexed citations
19.
Raz, Raanan, et al.. (2000). Recurrent Urinary Tract Infections in Postmenopausal Women. Clinical Infectious Diseases. 30(1). 152–156. 221 indexed citations
20.
Lightdale, Charles J., Jeffrey S. Wasser, Morton Coleman, et al.. (1979). Anticoagulation and high dose liver radiation.A preliminary report. Cancer. 43(1). 174–181. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by G.J. Ossenkoppele Breakdown of academic impact, for papers by Pietro Pioltelli Breakdown of academic impact, for papers by Michael Schleuning Breakdown of academic impact, for papers by Ulf‐Henrik Mellqvist Breakdown of academic impact, for papers by Katsuji Shinagawa Breakdown of academic impact, for papers by Norifumi Tsukamoto Breakdown of academic impact, for papers by Akihiko Yokohama Breakdown of academic impact, for papers by Vamsi Kota Breakdown of academic impact, for papers by Belinda R. Avalos Breakdown of academic impact, for papers by Federico Campigotto
Rankless by CCL
2026